{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:14:05Z","timestamp":1787958845312,"version":"build-2784847793"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec id=\"ab-hoi240076-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic value of changes in kidney function over time has yet to be defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi240076-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the prognostic importance of a decline in estimated glomerular filtration rate (eGFR) in a large cohort of patients with ATTR-CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi240076-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective, observational, single-center cohort study evaluated patients diagnosed with ATTR-CM at the National Amyloidosis Centre (NAC) in the UK who underwent an eGFR baseline assessment and a follow-up assessment at 1 year between January 2000 and April 2024. Data analysis was performed in June 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi240076-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was the risk of all-cause mortality associated with decline in kidney function (defined as a decrease in eGFR &amp;amp;gt;20%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi240076-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 2001 patients, mean (SD) age was 75.5 (8.4) years, and 263 patients (13.1%) were female. The median (IQR) change in eGFR was \u22125 mlL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (\u221212 to 1), and 481 patients (24.0%) experienced decline in kidney function. Patients who experienced decline in kidney function more often had the p.(V142I) genotype than patients with stable kidney function (99 [20.6%] vs 202 [13.3%];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and had a more severe cardiac phenotype at baseline, as evidenced by higher median (IQR) concentrations of serum cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP]: 2949 pg\/mL [1759-5182] vs 2309 pg\/mL [1146-4290];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; troponin T: 0.060 ng\/mL [0.042-0.086] vs 0.052 ng\/mL [0.033-0.074];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), while baseline median (IQR) kidney function was similar between the 2 groups (eGFR: 63 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      [51-77] vs 61 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      [49-77];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.41). Decline in kidney function was associated with a 1.7-fold higher risk of mortality (hazard ratio [HR], 1.71; 95% CI, 1.43-2.04;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), with a similar risk across the 3 genotypes (wild type: HR, 1.64; 95% CI, 1.31-2.04; p.(V142I): HR, 1.70; 95% CI, 1.21-2.39; non-p.(V142I): HR, 1.51; 95% CI, 0.87-2.61) (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.93) and the 3 NAC disease stages (stage 1: HR, 1.69; 95% CI, 1.22-2.32; stage 2: HR, 1.69; 95% CI, 1.30-2.18; stage 3: HR, 1.61; 95% CI, 1.11-2.35) (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.97). Decline in kidney function remained independently associated with mortality after adjusting for increases in NT-proBNP and outpatient diuretic intensification (HR, 1.48; 95% CI, 1.23-2.76;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi240076-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this retrospective cohort study, decline in kidney function was frequent in patients with ATTR-CM and was consistently associated with an increased risk of mortality, even after adjusting for established markers of worsening ATTR-CM. eGFR decline represents an independent marker of ATTR-CM disease progression that could guide treatment optimization in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2024.4578","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T13:30:26Z","timestamp":1731850226000},"page":"50","source":"Crossref","is-referenced-by-count":34,"title":["Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1001","volume":"10","author":[{"given":"Adam","family":"Ioannou","sequence":"first","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuf","family":"Razvi","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"},{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad U.","family":"Rauf","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Naharro","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Venneri","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salsabeel","family":"Kazi","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Pasyar","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina M.","family":"Luxh\u00f8j","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Petrie","sequence":"additional","affiliation":[{"name":"University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Moody","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Steeds","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Whelan","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lachmann","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"hoi240076r1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi240076r2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jcmg.2022.07.008","article-title":"Multi-imaging characterization of cardiac phenotype in different types of amyloidosis.","volume":"16","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"hoi240076r3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Failure"},{"issue":"12","key":"hoi240076r4","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","article-title":"Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.","volume":"24","author":"Patel","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"hoi240076r5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"Heart failure and kidney dysfunction: epidemiology, mechanisms and management.","volume":"12","author":"Schefold","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"hoi240076r6","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","article-title":"Renal impairment and outcomes in heart failure: systematic review and meta-analysis.","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"hoi240076r7","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi240076r8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jchf.2024.01.004","article-title":"Trajectories of kidney function in heart failure over a 15-year follow-up: clinical profiling and mortality.","volume":"12","author":"Zamora","year":"2024","journal-title":"JACC Heart Failure"},{"issue":"6","key":"hoi240076r9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Failure"},{"issue":"14","key":"hoi240076r10","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis.","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi240076r11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi240076r12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033094","article-title":"Multiorgan dysfunction and associated prognosis in transthyretin cardiac amyloidosis.","volume":"13","author":"Ioannou","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"hoi240076r13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ejhf.3094","article-title":"Albuminuria in transthyretin cardiac amyloidosis: prevalence, progression and prognostic importance.","volume":"26","author":"Ioannou","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"hoi240076r14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ejhf.3088","article-title":"Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: distinct from wild-type ATTR amyloidosis?","volume":"26","author":"Razvi","year":"2024","journal-title":"Eur J Heart Failure"},{"issue":"22","key":"hoi240076r15","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years.","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"31","key":"hoi240076r16","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis.","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"issue":"13","key":"hoi240076r17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction.","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"issue":"23","key":"hoi240076r18","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi240076r19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"hoi240076r20","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy.","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi240076r21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT.","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"1","key":"hoi240076r22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis.","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi240076r23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis.","volume":"37","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"issue":"11","key":"hoi240076r24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi240076r25","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"hoi240076r26","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1001\/jamacardio.2023.2010","article-title":"Tracking treatment response in cardiac light-chain amyloidosis with native T1 mapping.","volume":"8","author":"Ioannou","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"8","key":"hoi240076r27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jcmg.2023.02.019","article-title":"Tracking multiorgan treatment response in systemic AL-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping.","volume":"16","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"hoi240076r28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ejhf.2376","article-title":"Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT.","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Failure"},{"issue":"22","key":"hoi240076r29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.123.066506","article-title":"Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial.","volume":"148","author":"Chatur","year":"2023","journal-title":"Circulation"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2826720\/jamacardiology_ioannou_2024_oi_240076_1735232925.45109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:01:24Z","timestamp":1736334084000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2826720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.4578","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}